Supplemental Information

Long-term outcomes of autologous

skeletal myoblast cell-sheet transplantation

for end-stage ischemic cardiomyopathy

Satoshi Kainuma, Shigeru Miyagawa, Koichi Toda, Yasushi Yoshikawa, Hiroki Hata, Daisuke Yoshioka, Takuji Kawamura, Ai Kawamura, Noriyuki Kashiyama, Yoshito Ito, Hiroko Iseoka, Takayoshi Ueno, Toru Kuratani, Kei Nakamoto, Fusako Sera, Tomohito Ohtani, Tomomi Yamada, Yasushi Sakata, and Yoshiki Sawa

SUPPLEMENTAL MATERIAL

Long-term Outcomes of Autologous Skeletal Myoblast Cell-sheet Transplantation for End-stage Ischemic Cardiomyopathy

Satoshi Kainuma, MD, PhD[1]; Shigeru Miyagawa, MD, PhD[1]; Koichi Toda, MD, PhD[1]; Yasushi Yoshikawa, MD[1]; Hiroki Hata, MD, PhD[1]; Daisuke Yoshioka, M.D, PhD[1]; Takuji Kawamura, MD, PhD [1]; Ai Kawamura, MD, PhD [1]; Noriyuki Kashiyama, MD, PhD [1]; Yoshito Ito, MD, PhD [1]; Hiroko Iseoka, PhD [1]; Takayoshi Ueno, MD, PhD[1]; Toru Kuratani, MD, PhD[1]; Kei, Nakamoto, MD[2]; Fusako Sera, MD[2]; Tomohito Ohtani, MD, PhD[2]; Tomomi Yamada, PhD [3]; Yasushi Sakata, MD, PhD[2]; Yoshiki Sawa, MD, PhD[1]


Institutions and affiliations

[1] Department of Cardiovascular Surgery, Osaka University Graduate School of Medicine, Suita, Osaka, Japan

[2] Department of Cardiovascular Medicine, Osaka University Graduate School of Medicine, Suita, Osaka, Japan

[3] Department of Medical Innovation, Osaka University Hospital, Suita, Japan

**Supplemental Figures**

Supplemental Figure 1

Supplemental Figure 2

Supplemental Figure 3

A ROC curve analysis for eGFR

Sensitivity (%)

AUC=0.86

Optimal cutoff value=63 mL/min/1.73m²
Sensitivity = 69%
Specificity = 100%

1- specificity (%)

B ROC curve analysis for LVESVI

Sensitivity (%)

AUC=0.75

Optimal cutoff value = 70 ml/m²
Sensitivity = 50%
Specificity = 100%

1- specificity (%)

C ROC curve analysis for eGFR and LVESVI

Sensitivity (%)

AUC=0.95

Sensitivity = 75%
Specificity = 100%

1- specificity (%)

Supplemental Figure 4

Supplemental Figure legends

Supplemental Figure 1. Serial assessments of severity of mitral regurgitation and tricuspid regurgitation in the entire cohorts (A, B) and according to responders and non-responders (C, D).

Abbreviations: MR, mitral regurgitation; TR, tricuspid regurgitation

Supplemental Figure 2. Serial assessments of ventricular arrhythmias in the entire cohorts (A-C) and according to responders and non-responders (D-F): total number of heart beats (A, D), total number of PVCs (B, E), and percent PVC values (C, F). Data are presented as means± standard errors.

Abbreviations: PVC, premature ventricular contraction

Supplemental Figure 3. The receiver operating curve for preoperative eGFR (A), LVESVI (B), eGFR, and LVESVI (C) to determine the possibility to respond to the treatment.

Abbreviations: eGFR, estimated glomerular filtration rate; LVESVI, left ventricular end-systolic volume index

Supplemental Figure 4. CONSORT flowchart for selection of patients with ischemic cardiomyopathy who underwent skeletal myoblast cell-sheet transplantation.

Abbreviations: LV, left ventricular; HCM, hypertrophic cardiomyopathy